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Abstract A subset of patients with relapsing-remitting multiple sclerosis (RRMS) on therapy
with interferon beta (IFNβ) develop neutralising anti-drug antibodies (ADA) resulting in reduced,
or loss of, therapeutic efficacy. The aims were to characterise the relative contributions of
anti-IFNβ antibody isotypes to drug neutralising activity, ability of these antibodies to
cross-react with endogenous IFNβ, to form immune complexes and activate complement.
IFNβ-specific ADA were measured in plasma from RRMS patients treated with IFNβ1a
(Rebif®). Neutralisation of endogenous and therapeutic IFNβ by ADA was determined by IFNβ
bioassay. IFNβ-ADA profile was predominantly comprised of IgG1 and IgG4 antibody isotypes.
The contribution of IgG4-ADA towards neutralising activity was found to be minimal. Neutralising
IFNβ-ADA blocks endogenous IFNβ activity. ADA interaction with therapeutic IFNβ results ine for Drug Safety Science and Institute of Translational Medicine, Department of Molecular and Clinical
Sherrington Buildings, Ashton Street, Liverpool L69 3GE, UK. Fax: +44 151 7945540.
pool.ac.uk (J. Sathish).
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178 S. Sethu et al.immune complex formation and complement activation. In summary, IgG1 and IgG4 IFNβ-ADA
have the ability to neutralise therapeutic and endogenous protein and to activate complement.
© 2013 Authors. Published by Elsevier Inc. Open access under CC BY license.1. Introduction
Multiple sclerosis (MS) is a chronic inflammatory demyelin-
ating disease of the central nervous system and the most
common form of MS at onset is relapsing-remitting MS
(RRMS) [1]. Clinical trials have demonstrated the efficacy of
recombinant interferon beta (IFNβ1a and IFNβ1b), in
reducing relapse rate and disease progression in RRMS
patients [2,3]. A major limitation with continuous IFNβ
treatment is the development of anti-drug antibodies (ADA)
[4–6]. ADA can be non-neutralising (N-NAbs) or neutralising
(NAbs) depending on their ability to block bioactivity of
therapeutic IFNβ by interacting at sites that are crucial for
drug-target interaction. In general, ADA against biologics
can result in loss of bioactivity, altered pharmacokinetics,
neutralisation of endogenous counterparts, infusion reac-
tions, hypersensitivity and anaphylaxis [7–10].
ADA against therapeutic IFNβ are reported to be
predominant of the immunoglobulin G (IgG) class. Reports
on the distribution of IgG subclasses (IgG1-4) of IFNβ-
specific NAbs in MS patients on IFNβ therapy are limited
[11,12]. Type I interferons, including IFNβ, are crucial in
the regulation of host immune responses. The potential for
neutralisation of endogenous IFNβ by IFNβ1a-specific ADA
(IFNβ-ADA) is unclear. Interaction of ADA with the thera-
peutic can result in the formation of immune complex (IC)
that can potentially activate complement. Complement
factors are a group of plasma proteins that play a pivotal
role in both innate and adaptive immunity [13]. There is
considerable evidence for the influence of activated
complement in antigen processing and presentation
[14,15]. Therefore, increase in complement activation
can enhance antigen processing and presentation which
may contribute to the progression of immunogenic re-
sponses to biologics.
In this study, our aim was to determine the immunoglob-
ulin types/subtypes of IFNβ-ADA in samples from patients
treated with IFNβ and their relative contribution in
neutralising IFNβ bioactivity, the potential of NAb to cross
react with endogenous IFNβ and the ability of ADA-IFNβ
immune complexes to activate the complement cascade.2. Materials and methods
2.1. Chemicals and reagents
All chemicals and reagents used in the study, unless
specified otherwise, were obtained from Sigma-Aldrich,
UK.. anti-human MxA antibody (Santa Cruz Biotechnologies,
USA); anti-rabbit and anti-mouse HRP-conjugated secondary
antibody (Sigma Aldrich, UK); mouse anti-human β-actin
(Abcam, UK); THP-1 — human acute monocytic leukaemiacell line (American Type Culture Collection, #TIB-202™);
IFNβ1a formulation — Rebif® (EMD Serono, Inc. and Pfizer,
Inc.).
2.2. Subject details
Ten healthy donors and nineteen RRMS patients with history
of IFNβ therapy as detailed in Table 1 were chosen for this
study from The Walton Centre NHS Foundation Trust, UK.
Approval for the study was acquired from the Liverpool local
research ethics committee and informed written consent
was obtained from each donor. Plasma and serum fractions
obtained from peripheral venous blood samples were stored
in aliquots at −80 °C until further use. Fresh aliquots of
serum samples were used for each experiment to ensure that
samples did not undergo more than one freeze–thaw cycle.
2.3. Detection and quantification of total and
IFNβ-specific immunoglobulins
Total IgG and IgM in the plasma were quantified by sandwich
type enzyme-linked immunosorbent assay (ELISA) using
human IgG and IgM ELISA quantitation kits (Bethyl Labora-
tories, Inc. USA), and total IgG subclass levels in the plasma
were quantified by ELISA using human IgG subclass profile kit
(Invitrogen — Life Technologies, UK) according to manufac-
turer's instructions. IFNβ-specific immunoglobulins (IgG and
IgM) and IgG subclass were quantified using ELISA according
to manufacturer's instructions (IgG/IgM — Bethyl Laborato-
ries, Inc., USA; IgG subclass — Cygnus Technologies, Inc.,
USA) with the following modifications. IFNβ1a (Rebif®,
1.5 μg/ml) was coated and the plasma dilutions used were
1:20 for IgG/IgG subclass and 1:2 for IgM detection. The
absolute concentrations for total and IFNβ-specific immuno-
globulins types were calculated based on the standards
provided in the kit, except for IFNβ-specific IgG subclass
where the analysis was based on optical density values.
2.4. Neutralisation assay — IFNβ induced
MxA bioassay
Myxovirus resistance protein A (MxA) expression is a well-
known biomarker for IFNβ bioactivity [16]. The neutralising
potential of IFNβ-ADA was determined by measuring IFNβ-
induced (MxA) protein expression in THP-1 cells, using western
blotting. Preliminary experiments in our laboratory established
that IFNβ induced, in a dose-dependent manner, the expres-
sion of MxA protein in THP-1 cells (data not shown). Briefly,
IFNβ1a (Rebif®) 100 U/ml was incubated with diluted patient
plasma for 1 hour at 37 °C followed by its addition to THP-1
cells in culture and further incubated for 18 hours at 37 °C.
The cells were subjected to detergent lysis, 20 μg of protein
Table 1 Details and history of IFNβ therapy.
Donor ID Age Sex Group IFNβ therapy
status
Rebif (s.c.)
dose (μg)
Duration (months a)
Therapy|Since WDL
D9 24 F Healthy N.A. N.A. N.A. N.A.
D11 42 M Healthy N.A. N.A. N.A. N.A.
D18 47 F Healthy N.A. N.A. N.A. N.A.
D19 30 F Healthy N.A. N.A. N.A. N.A.
D20 43 F Healthy N.A. N.A. N.A. N.A.
D21 33 F Healthy N.A. N.A. N.A. N.A.
D22 43 M Healthy N.A. N.A. N.A. N.A.
D23 30 F Healthy N.A. N.A. N.A. N.A.
D24 27 M Healthy N.A. N.A. N.A. N.A.
D25 32 F Healthy N.A. N.A. N.A. N.A.
D4 47 M RRMS ON 22 48 N.A.
D5 57 M RRMS ON 44 32 N.A.
D6 30 F RRMS ON 44 N120 N.A.
D8 43 M RRMS ON 22 N120 N.A.
D12 32 F RRMS ON 44 141 N.A.
D16 56 F RRMS ON 22 N120 N.A.
D17 37 F RRMS ON 44 96 N.A.
D26 50 F RRMS ON 22 60 N.A.
D27 45 F RRMS ON 22 120 N.A.
D2 55 F RRMS WD 22 43 5
D3 46 M RRMS WD 22 24 57
D7 54 M RRMS WD 22 36 44
D10 30 M RRMS WD 22 84 48
D13 49 M RRMS WD 22 15 34
D14 43 F RRMS WD 22 12 13
D15 43 M RRMS WD 22 72 53
D28 46 F RRMS WD 22 48 31
D29 53 F RRMS WD 22 36 57
D30 41 F RRMS WD 22 18 54
Abbreviations: RRMS — relapsing-remitting multiple sclerosis; Rebif — IFNβ1a; s.c. — subcutaneous; WD — withdrawn; WDL- withdrawal;
ON — ongoing; N.A. — not applicable; F — female; M — male.
a Months calculated until the month of sample collection.
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expression by western blotting using 1:500 rabbit anti-human
MxA antibody (Santa Cruz Biotechnologies, USA) followed
by 1:5000 HRP-conjugated anti-rabbit secondary antibody
(Sigma Aldrich, UK), developed with enhanced chemilumines-
cence (ECL) and visualised by autoradiography. Intensities of
immunoreactive bands were quantified by densitometry
(TotalLabTL120software — Nonlinear Dynamics Ltd.,
Newcastle, UK).2.5. Cross reactivity of ADA to endogenous IFNβ
The potential of ADA to cross react with endogenous IFNβ
was assessed using lipopolysaccharide (LPS) — 1 μg/ml and
polyinosinic–polycytidylic acid [poly(I:C)] — 10 μg/ml trig-
gered IFNβ secretion by THP-1 cells and subsequent MxA
expression due to the autocrine effect of the secreted IFNβ
on the THP-1 cells (Fig. 4a). Cross reactivity of ADA was
assessed by co-incubating diluted ADA positive patient
plasma with LPS and poly(I:C) in THP-1 cells followed byculture at 37 °C for 24 hours. After 24 hours, MxA levels
were quantified by western blotting as described earlier.
2.6. IgG4 depletion
Human IgG4 was depleted from plasma using human
IgG4-specific affinity resin (Capture select, BAC BV, The
Netherlands). Briefly, total plasma was incubated with the
resin for 3 minutes at room temperature in a Mobicol “F”
spin column (MoBiTec GmbH, Germany). Subsequently,
plasma sample depleted of IgG4 was collected by brief
centrifugation. Total IgG4 depleted (80–99%) plasma was
subsequently used for the experiments.
2.7. Measurement of ADA-IFNβ immune complex
Formation of ADA-IFNβ immune complex in vitro was
induced by incubating IFNβ1a (Rebif®) with patient serum
for 1 hour at 37 °C followed by assessing the amount of IgG
based complexes bound to C1q using IMTEC-CIC IgG ELISA kit
Figure 1 Immunoglobulin types/subtypes of therapeutic IFNβ-ADA. Total and IFNβ-specific IgG (a and c) and IgM (b and d) in the
plasma of healthy donors (healthy) and RRMS patients (RRMS) were determined by ELISA. Data points▼ in graph (a) are categorised as
IFNβ-specific IgG based ADA positive samples. (e) Total IgG subclass in healthy and RRMS plasma samples. (f) IFNβ-specific IgG
subclass levels in 8 ADA positive samples detected. (g) Proportion of IFNβ-specific IgG subclass in each ADA positive plasma sample.
Statistical analyses include t-test and ANOVA. ⁎p = 0.0352 (t-test unpaired); ⁎⁎p = 0.0045 (ANOVA); healthy — n = 10; RRMS — n = 19.
The data point in each graph is a mean of triplicate measurements and is a representative of three independent experiments.
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mbH, Germany) according to manufacturer's instructions.
2.8. Measurement of immune complex induced C3a
ADA-IFNβ immune complexes were induced as described above
and activated complement factor, C3a, in these samples was
measured by using C3a ELISA kit (Hycult Biotech, Netherlands)
according to manufacturer's instructions.
2.9. Statistical analysis
Datawere analysedwith appropriate statistical tests (unpaired/
paired t-test and ANOVA) as indicated in the figure legends
using GraphPad Prism v.5.
3. Results
3.1. IFNβ1a-specific ADA are predominantly of the
IgG1 and IgG4 subclass
Eight out of nineteen RRMS patients had detectable levels of
IFNβ1a-specific IgG (Fig. 1a). The samples were categorised as
ADA positive when the IFNβ1a-specific IgG concentrations
were above a threshold value of the mean and two standard
deviations of the value in healthy control plasma. The
concentrations of ADA ranged between 0.3 μg/ml and
2.0 μg/ml and were of IgG type and not IgM (Figs. 1a and b).
There were no significant differences in the levels of total IgG
and IgM between the healthy controls and RRMS samples
(Figs. 1c and d). Immunoglobulin G subclass typing revealed
that levels of IFNβ1a-specific IgG1 and IgG4 in the plasma of 8
ADA positive samples were significantly higher compared to
IgG2 and IgG3 (Fig. 1f). Distribution of IFNβ1a-specific IgGFigure 2 Neutralisation potential of therapeutic IFNβ-ADA. Imm
Therapeutic IFNβ (100U Rebif) pre-incubated with 1:10 dilution of p
ADA (ADA − ve) for 1 hour at 37 °C was added to THP-1 cells for
separated by SDS–PAGE and western immunoblotting performed.
indicates cell lysates prepared from cells without any treatment and
D2–D30 are lysate samples from cells incubated with the plasma
independent experiments.subclasses for each of the samples indicated that both IgG1
and IgG4 at varying levels predominantly contributed to the
ADA followed by IgG3 and IgG2 (IgG3 N IgG2, Fig. 1g). The
ADA profile in the ADA-positive donor (D29) was found to be
primarily made up of IFNβ1-specific IgG1 and IgG3 with IFNβ1-
specific IgG4 being undetectable (Fig. 1g). There were no
significant differences in the total IgG subclass levels between
healthy and RRMS samples (Fig. 1e).
3.2. Neutralising potential and cross reactivity
of IFNβ-ADA
We used IFNβ-induced intracellular MxA expression in THP-1
cells to assess the neutralisation potential of the IFNβ-specific
ADA. Our data indicate that 7 out of 8 ADA-positive samples had
the potential to neutralise IFNβ1a (Rebif®) inducedMxA (Fig. 2).
Sample D29 did not neutralise the IFNβ1a indicating that the
ADAwere of the non-neutralising type. As expected, none of the
samples from ADA negative and healthy donors neutralised
IFNβ-induced MxA (Fig. 2). Our results were consistent with the
data obtained (data not shown) from other neutralisation assays
carried out independently at National Institute for Biological
Standards and Control (NIBSC), UK.
While earlier association studies have implicated IgG4 ADA
as having greater neutralisation potential compared to other
IgG subclasses, this has not been directly tested. We depleted
IgG4 from ADA-positive plasma (samples D3, D10, D13,
D14, D15, D28 and D30) and compared IFNβ neutralisation
between total plasma and IgG4 depleted plasma using MxA
assay (Fig. 3). Based on the results, depleting IgG4 in D3, D13,
D14 and D28 contributed to a partial (12–30%) reduction in its
neutralisation potential. The IgG4 depleted samples of D10, D15
and D30 exhibited an increase (2–30%) in neutralisation.
Our observations from this study indicate that IgG4 may partly
or not contribute to the neutralisation activity of neutralisingunoblot shows IFNβ-induced MxA protein levels in THP-1 cells.
lasma samples of healthy and RRMS with (ADA + ve) and without
18 hours. Proteins from whole cell lysates of these cells were
Membranes were probed for human MxA and β-actin. “Ctrl”
“IFNβ” indicates lysates from cells treated with 100U Rebif only.
and IFNβ mixture. The images are representative of three
Figure 3 Neutralisation potential of IgG4 based therapeutic
IFNβ-ADA. (a) “Neutralisation (%)” is the percentage based
obtained on densitometry analysis immunoblot as shown in Fig. 3b
assessing IFNβ-induced MxA neutralisation by RRMS ADA + ve
plasma samples with and without IgG4 relative to “IFNβ” only
category. The percentage indicates the difference in the
neutralisation potential of IgG4 depleted plasma compared to its
respective non-depleted fraction. (b) Immunoblot exhibits vari-
able differences in the potency of ADA positive plasma samples
with and without IFNβ-specific IgG4 to neutralise IFNβ-induced
MxA protein levels in THP-1 cells. Therapeutic IFNβ (100U Rebif)
pre-incubated with diluted of plasma from 8 RRMS ADA + ve
samples (1:1000 — D3, D10, D13, D14, D15 and 1:10 — D28, D30)
with (Pre) and without (Post) IgG4 for 1 hour at 37 °C was added
to THP-1 cells for 18 hours. Proteins from whole cell lysates of
these cells for each category were electrophoretically (SDS–PAGE)
separated and probed for human MxA. β-Actin probed for all the
samples served as loading controls. “Ctrl” indicates cell lysates
prepared from cells without any treatment and “IFNβ” indicate
lysates from cells treated with 100U Rebif only. The images are
representatives of three independent experiments.
182 S. Sethu et al.IFNβ-specific ADA and that this effect can vary between
patients.
Eight ADA-positive samples were tested for their cross
reactivity to endogenous IFNβ. Five (D3, D10, D13, D14 and
D15) out of the eight samples neutralised TLR4/3 (LPS/
poly(I:C)) induced endogenous IFNβ at varying degrees (~47%
to ~77%) as seen by the reduction in the levels of MxA
compared to its positive control (Lane 2 — Fig. 4). Our results
indicate that ADA generated in response to therapeutic IFNβ
can neutralise endogenous IFNβ.
3.3. Complement activation by ADA-IFNβ
immune complex
Immune complexes between a biologic and ADA have the
potential to activate complement by first binding to comple-
ment component C1q, which then leads to the induction ofactivated complement. Optimal C1q binding of the ADA-IFNβ
immune complex was observed at an antigen–antibody
(IFNβ1a:ADA) ratio of 5:1 (Fig. 5a). A significant increase in
the ADA-IFNβ immune complex formation was observed
following IFNβ1a incubation in the ADA-positive serum
samples (Fig. 5b). The degree of immune complex formation
in individual samples was variable with values ranging from 0.2
to 2 fold increase from baseline (Fig. 5c). Elevated C1q binding
was accompanied by a significant increase in the level of C3a
in the serum samples incubated with IFNβ1a (Figs. 5d and
e). These results demonstrate that IFNβ1a-specific ADA
can form immune complexes with IFNβ1a and activate
complement.4. Discussion
IFNβ is one of the first line therapies used in the
management of RRMS. The development of neutralising
ADA has been reported with both IFNβ1a (2–39%) and IFNβ1b
(38–42%) therapy [6]. In the current study, the immuno-
globulin types of IFNβ-specific N-NAbs and NAbs detected
were IgGs, with no detectable levels of IgM. It is however
important to note that plasma samples were collected from
individuals, most of whom had been on IFNβ therapy for
many years. It is possible that IgM-ADA might have been part
of the early/initiation phase (first few months after
initiation of therapy) of an immunogenic response and
would then have switched to IgG-ADA in the ADA positive
samples. We have shown the presence of both IgG1 and
IgG4-ADA contributing to the IFNβ-specific ADA profile.
Earlier studies have shown a predominance of IgG4-ADA
against IFNβ1a preparations [12] and, IgG2 and IgG4-ADA to
IFNβ1b preparation [11]. These observations are similar to
the immunogenic responses against glatiramer acetate (GA)
treatment in RRMS which has shown predominance of
IgG4-ADA [17,18]. The presence or an increase in the
IgG4-ADA titre has been suggested to be associated with
increased neutralisation potential of ADA [11]. In this study,
we show that IgG4-ADA are less likely to be the major
contributor to neutralisation potential of ADA despite the
presence of increased titre of the IgG4 based IFNβ-ADA. Our
data also suggest that IgG4-ADA are not always associated
with neutralisation potential of IFN-specific ADA. This needs
to be tested further with increased sample size and with
purified IFNβ-specific IgG4. In addition, longitudinal studies
are necessary to better understand the evolution of IgG
subclass specific ADA and their neutralising capabilities.
Neutralising anti-drug antibodies against therapeutic
thrombopoietin and epoetin have the ability to cross react
with endogenous proteins and by compromising their bioac-
tivity, they can lead to serious clinical consequences [8,19].
Neutralising ADA generated to either IFNβ1a or IFNβ1b can
cross react and neutralise the activity of both these forms of
IFNβ [20,21]. A recent report showed that nAbs triggered by
both IFNβ1a and IFNβ1b therapy were able to neutralise
fibroblast derived endogenous IFNβ [22,23]. Here, we have
shown in an in vitro model that therapeutic IFNβ-specific
neutralising ADA were able to neutralise endogenous IFNβ
bioactivity in monocytic cells. The endogenous IFNβ activity
was not completely neutralised compared to therapeutic
IFNβ, suggesting that perhaps the level of endogenous IFNβ
Figure 4 IFNβ-specific ADA cross reacts and neutralises endogenous IFNβ-induced bioactivity. (a) Bioactivity of endogenous IFNβ
was assessed by triggering IFNβ induced MxA by TLR4/3 (LPS — 1 μg/ml)/(poly(I:C) — 10 μg/ml) activation. Cross reactivity of ADA to
endogenous IFNβ was studied by investigating whether ADA were able to block or inhibit the induction of MxA in this system.
(b) Immunoblot image shows MxA protein levels induced by LPS and poly(I:C) (LPS + PIC) stimulation for 24 hours in THP-1 cells.
Induction of MxA is as a result of endogenous Type 1 interferons, including IFNβ triggered by LPS + PIC. The immunoblot also indicates
the changes in the level of induced MxA when the cells were co-incubated with 1:10 dilution of plasma samples from 8 RRMS ADA + ve
(D3, D10, D13, D14, D15, D28, D29 and D30) individuals along with LPS + PIC. Proteins from whole cell lysates for each category were
electrophoretically (SDS–PAGE) separated and probed for human MxA. β-Actin probed for all the samples served as loading controls.
“Ctrl” indicates cell lysates prepared from cells without any treatment and “LPS + PIC” indicates lysates from cells treated with
LPS + PIC only. “Neutralisation (%)” is the percentage (densitometric analysis) of LPS + PIC induced MxA neutralised by RRMS
ADA + ve plasma samples relative to “LPS + PIC” only category. Immunoblot shown here is a representative of three independent
experiments.
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the ADA. Neutralisation of endogenous IFNβ could have a
potential impact on the integrity of the host immune system,
could increase the susceptibility to viral infections and may
affect the physiological role of endogenous IFNβ in various
organ systems, including the CNS. This can be of particular
significance when considering the fact that high titres of NAbs
to IFNβ were found to last for many years after cessation of
IFNβ therapy [5,24].
Antigen–antibody based immune complex triggers clas-
sical complement activation cascade with the release of
activated complement factors including C3a and C5a. Our
data show that interaction of ADA with therapeutic IFNβ
resulted in immune complex formation and activated
complement cascade following binding to C1q. Activated
complements, such as C3a and C5a, have been implicated in
enhancing antigen processing and presentation [14,15] and
in the maintenance of tolerance [25]. Enhanced antigen
uptake, processing and presentation may be major contrib-
uting factors in the initiation and progression of immuno-
genic response to biologics. Complement activation may
actively facilitate this process and could potentially favour
the development of ADA with increased neutralising
potential. It is interesting to note that the incidence of
ADA is higher with IFNβ preparations which are administered
subcutaneously (e.g. Rebif) compared to the intramuscularroute (e.g. Avonex) [26]. It is possible that immune complexes
between the injected IFNβ and ADA can activate comple-
ment in the subcutaneous interstitium and gain access to
skin resident APCs such as Langerhans cells and dermal
dendritic cells. Such interactions between immune com-
plexes, activated complement and skin APCs could enhance
antigen processing and presentation of the therapeutic
protein and enable the progression of immunogenicity. This
could also be a mechanism by which low affinity and N-NAbs
lead to the development of NAbs through immune complex
formation and enhanced antigen processing/presentation.
In the current study we observed sample D29 which had very
limited or no neutralising potential but was able to form IC
and activate complement in the presence of IFNβ. Based on
this observation, we speculate that if a patient with N-NAbs
continues to receive IFNβ therapy, immune complexes can
be formed which through efficient antigen processing and
presentation, and in combination with epitope spreading
mechanisms, may eventually lead to the production of NAbs
with consequences for continuation of therapy. Altered
complement status and activated complement has been
associated with MS [27,28]. Our observation of complement
activation by IFNβ in ADA positive samples raises the
possibility that repeated administration of IFNβ to ADA
positive patients could cause additional alterations in the
complement status in these patients. The clinical impact of
Figure 5 Therapeutic ADA-IFNβ immune complex activates complement system. (a) Ag[IFNβ]:Ab[ADA] ratio (IFNβ:ADA) at which
immune complexes (IC) were formed by incubating IFNβ with serum containing ADA for 1 hour at 37 °C (n = 2). Graphs indicate the
levels of ADA-IFNβ immune complexes bound to C1q (b and c) and subsequent changes in the level of C3a (d and e) in 8 RRMS ADA + ve
(D3, D10, D13, D14, D15, D28, D29 and D30) serum samples. Statistical analyses include t-test and ANOVA. ⁎p = 0.0180 (t-test paired);
⁎⁎p b 0.0001 (t-test paired); #p b 0.0001 (ANOVA); n = 8. The data point in each graph is a mean with standard deviation of triplicate
measurements and is a representative of three independent experiments.
184 S. Sethu et al.such complement activation on MS disease progression is
currently unknown and merits further investigation.5. Conclusion
The development of neutralising anti-drug antibody devel-
opment to biologics in general and interferon beta therapy
in particular poses a significant clinical problem in terms of
loss of efficacy and other adverse reactions. In the present
study we have characterised the neutralising activity, IgG
subclass profile, the potential for cross reactivity to
endogenous interferon and complement activation of anti-
drug antibodies to interferon beta in multiple sclerosis
patients. Understanding the evolution of anti-drug antibody
immune response and associated adverse immune outcomescan inform the development of better clinical approaches
and regimens for biologics therapy.
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